JP2021514979A5 - - Google Patents

Info

Publication number
JP2021514979A5
JP2021514979A5 JP2020544853A JP2020544853A JP2021514979A5 JP 2021514979 A5 JP2021514979 A5 JP 2021514979A5 JP 2020544853 A JP2020544853 A JP 2020544853A JP 2020544853 A JP2020544853 A JP 2020544853A JP 2021514979 A5 JP2021514979 A5 JP 2021514979A5
Authority
JP
Japan
Prior art keywords
day
cancer
composition according
item
effective dose
Prior art date
Application number
JP2020544853A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019165458A5 (https=
JP2021514979A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019643 external-priority patent/WO2019165458A1/en
Publication of JP2021514979A publication Critical patent/JP2021514979A/ja
Publication of JPWO2019165458A5 publication Critical patent/JPWO2019165458A5/ja
Publication of JP2021514979A5 publication Critical patent/JP2021514979A5/ja
Priority to JP2023195862A priority Critical patent/JP2024012649A/ja
Withdrawn legal-status Critical Current

Links

JP2020544853A 2018-02-26 2019-02-26 Ｃｈｋ１阻害剤を含む癌の治療方法 Withdrawn JP2021514979A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023195862A JP2024012649A (ja) 2018-02-26 2023-11-17 Ｃｈｋ１阻害剤を含む癌の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862635459P 2018-02-26 2018-02-26
US62/635,459 2018-02-26
US201862650192P 2018-03-29 2018-03-29
US62/650,192 2018-03-29
US201862743993P 2018-10-10 2018-10-10
US62/743,993 2018-10-10
PCT/US2019/019643 WO2019165458A1 (en) 2018-02-26 2019-02-26 Methods of treatment of cancer comprising chk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023195862A Division JP2024012649A (ja) 2018-02-26 2023-11-17 Ｃｈｋ１阻害剤を含む癌の治療方法

Publications (3)

Publication Number Publication Date
JP2021514979A JP2021514979A (ja) 2021-06-17
JPWO2019165458A5 JPWO2019165458A5 (https=) 2022-03-04
JP2021514979A5 true JP2021514979A5 (https=) 2022-03-04

Family

ID=67687903

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544853A Withdrawn JP2021514979A (ja) 2018-02-26 2019-02-26 Ｃｈｋ１阻害剤を含む癌の治療方法
JP2023195862A Pending JP2024012649A (ja) 2018-02-26 2023-11-17 Ｃｈｋ１阻害剤を含む癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023195862A Pending JP2024012649A (ja) 2018-02-26 2023-11-17 Ｃｈｋ１阻害剤を含む癌の治療方法

Country Status (9)

Country Link
US (1) US20200397796A1 (https=)
EP (1) EP3758678A4 (https=)
JP (2) JP2021514979A (https=)
KR (1) KR20200126388A (https=)
CN (1) CN112469391A (https=)
AU (1) AU2019224164A1 (https=)
CA (1) CA3092079A1 (https=)
MX (1) MX2020008881A (https=)
WO (1) WO2019165458A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3609884A4 (en) 2017-04-10 2021-01-06 Sierra Oncology, Inc. CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH
US20220226338A1 (en) * 2019-05-14 2022-07-21 Sierra Oncology, Inc. Methods of Treating Cancer Using CHK1 Inhibitors
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
AU2021325905A1 (en) * 2020-08-12 2023-04-13 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
EP2755482B1 (en) * 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
RU2659786C2 (ru) * 2012-05-15 2018-07-04 Кансер Ресёрч Текнолоджи Лимитед 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
EP3609884A4 (en) * 2017-04-10 2021-01-06 Sierra Oncology, Inc. CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH
CA3065803A1 (en) * 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies

Similar Documents

Publication Publication Date Title
JP2021514979A5 (https=)
AU2019396895B2 (en) Combination of antibody-drug conjugate with PARP inhibitor
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
CN113573736B (zh) 经修饰的微rna和它们在治疗癌症中的用途
JP2019521087A5 (https=)
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
WO2021063332A1 (zh) 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
JP2020516693A5 (https=)
TW202214243A (zh) 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用
WO2023095929A1 (ja) 悪性腫瘍治療薬
JP2023542065A (ja) 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ
JPWO2019165458A5 (https=)
CN110522753A (zh) 一种新型抗肿瘤药物组合物、制剂和应用
WO2019114785A1 (zh) Pd-1抗体用于治疗肿瘤的用途
US20240180910A1 (en) Method for treating cancer with a chemotherapeutic modifier
CN113840608A (zh) Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
Di Maria et al. Applying molecular hybridization to design a new class of pyrazolo [3, 4-d] pyrimidines as Src inhibitors active in hepatocellular carcinoma
Liu et al. Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy
TW201513870A (zh) 含伊立替康鹽酸鹽水合物之抗腫瘤劑
US20220323443A1 (en) Combination therapy for cancer treatment
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
JPWO2021161262A5 (https=)
CN112870365A (zh) Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途
Li et al. 3H-3000, an FGFR2B-specific monoclonal antibody, shows superior tumor killing in vivo
JPWO2022043895A5 (https=)